Establishing a detailed pharmacological basis of Nav1.5 and Nav1.7 channels can provide valuable insight into the drug’s action for developing safe and effective therapies to treat arrhythmia and to alleviate pain. The gene discussed is SCN5A; the disease is cardiac arrhythmia.